Author

Esther Eromosele

Observed name: E. Eromosele

OpenAlex ID: A5080427966

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

2024 · Nirav N. Shah, Richard T. Maziarz, et al. · Blood · 8

P1134: Bispecific Anti-cd20/19 Car-t – Zamtocabtagene Autoleucel for Relapsed/refractory Dlbcl – Interim Analysis Results of Daly-ii-usa Study

2023 · Nirav Shah, Richard Maziarz, et al. · HemaSphere · 6

105 | Interim Results of Tandem Cd20‐cd19‐directed Non‐cryopreserved Car‐t Cells—zamtocabtagene Autoleucel in Relapsed/refractory Diffuse Large B Cell Lymphoma

2025 · N. N. Shah, R. T. Maziarz, et al. · Hematological Oncology · 1

Tandem CD20-CD19-Directed Non-Cryopreserved CAR T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Interim Results from a Phase 2 Pivotal Study (DALY II USA)

2025 · Nirav N. Shah, Richard T Maziarz, et al. · Transplantation and Cellular Therapy · 1

89 | Tandem Cd20‐19‐directed Non‐cryopreserved Car‐t Cells–zamtocabtagene Autoleucel (zamto‐cel)—in Patients With Relapsed/refractory Cns Lymphoma in Daly Ii Us Study

2025 · P. B. Johnston, D. B. Miklos, et al. · Hematological Oncology

Bispecific Anti‐cd20/19 Car‐t—zamtocabtagene Autoleucel for Relapsed/refractory Dlbcl—interim Analysis Results of Daly‐ii‐usa Study

2023 · M. Ulrickson, D. B. Miklos, et al. · Hematological Oncology

Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy: Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/ Refractory (R/R) DLBCL (DALY II USA NCT04792489)

2023 · Nirav N. Shah, Richard T Maziarz, et al. · Transplantation and Cellular Therapy

Works count: 7

Citation count: 16

H-index: 2

I10-index: